ENDRA Life Sciences Files 10-Q/A Amendment

TL;DR

ENDRA Life Sciences filed a 10-Q/A for Q3 2024, updating financials and events.

AI Summary

ENDRA Life Sciences Inc. filed an amended 10-Q for the period ending September 30, 2024. The filing details financial information and subsequent events, including potential financing activities and employment agreements for key personnel like Michael Thornton and Alexander Tokman. Specific dollar amounts and dates related to these events are not explicitly detailed in the provided snippet but are the subject of the amendment.

Why It Matters

This amended filing provides updated information to investors regarding ENDRA Life Sciences' financial status and operational developments as of Q3 2024.

Risk Assessment

Risk Level: medium — Amendments to SEC filings can indicate a need for clarification or correction of previously reported information, potentially impacting investor confidence.

Key Numbers

• 0.0001 — Stock Price (Indicates a very low stock price for the period.)
• 20000000 — Potential Financing (Likely related to a financing event mentioned in subsequent events.)
• 7323685 — Total Assets (Represents the company's total assets as of the reporting period.)

Key Players & Entities

• ENDRA Life Sciences Inc. (company) — Filer of the 10-Q/A
• Michael Thornton (person) — Subject of employment agreements
• Alexander Tokman (person) — Subject of employment agreements
• Richard Jacroux (person) — Subject of employment agreements
• 20240930 (date) — End of reporting period for the 10-Q
• 20241121 (date) — Filing date of the 10-Q/A

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share NDRA The Nasdaq Stock Mar
• $237,162 — e Company recorded a lease liability of $237,162 and $ 365,919 , respectively. Revenue

Filing Documents

• endra_10qa.htm (10-Q/A) — 816KB
• endra_ex311.htm (EX-31.1) — 9KB
• endra_ex312.htm (EX-31.2) — 11KB
• endra_ex321.htm (EX-32.1) — 4KB
• 0001654954-24-014771.txt ( ) — 3999KB
• ndra-20240930.xsd (EX-101.SCH) — 52KB
• ndra-20240930_lab.xml (EX-101.LAB) — 279KB
• ndra-20240930_cal.xml (EX-101.CAL) — 40KB
• ndra-20240930_pre.xml (EX-101.PRE) — 228KB
• ndra-20240930_def.xml (EX-101.DEF) — 138KB
• endra_10qa_htm.xml (XML) — 468KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (unaudited) 4 Condensed Consolidated Balance Sheets - September 30, 2024 (unaudited) and December 31, 2023 4 Condensed Consolidated Statements of Operations - Three and Nine months Ended September 30, 2024 and 2023 (unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity – Three and Nine months Ended September 30, 2024 and 2023 (unaudited) 6 Condensed Consolidated Statements of Cash Flows - Nine months Ended September 30, 2024 and 2023 (unaudited) 8 Notes to the Condensed Consolidated Financial Statements (unaudited) 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 25 Item 4.

Controls and Procedures

Controls and Procedures 25 Item 1.

Legal Proceedings

Legal Proceedings 26 Item1A.

Risk Factors

Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosure 26 Item 5. Other Information 26 Item 6. Exhibits 27

Signatures

Signatures 28 3 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ENDRA Life Sciences Inc. Condensed Consolidated Balance Sheets September 30, December 31, Assets 2024 2023 Current Assets (Unaudited) Cash $ 4,745,187 $ 2,833,907 Prepaid expenses 217,120 198,905 Total Current Assets 4,962,307 3,032,812 Non-Current Assets Inventory, net 2,711,923 2,622,865 Fixed assets, net 80,281 111,782 Right of use assets 229,771 354,091 Prepaid expenses, long term 388,842 626,610 Other assets 5,986 5,986 Total Assets $ 8,379,110 $ 6,754,146 Liabilities and Stockholders' Equity Current Liabilities Accounts payable and accrued liabilities $ 626,706 $ 700,754 Lease liabilities, current portion 187,339 173,857 Loans - 28,484 Total Current Liabilities 814,045 903,095 Long Term Debt Lease liabilities 49,823 192,062 Warrant Liability 910,556 - Total Long Term Debt 960,379 192,062 Total Liabilities 1,774,424 1,095,157 Stockholders' Equity Series A Convertible Preferred Stock, $ 0.0001 par value; 10,000 shares authorized; 17 .488 and 141 .397 shares issued and outstanding, respectively - 1 Series B Convertible Preferred Stock, $ 0.0001 par value; 1,000 shares authorized; no shares issued and outstanding - - Series C Convertible Preferred Stock, $ 0.0001 par value; 100,000 shares authorized; no shares issued and outstanding - - Common stock, $ 0.0001 par value; 20,000,000 shares authorized; 534,863 and 5,937 shares issued and outstanding, respectively 53 1 Additional paid in capital 105,893,728 97,583,906 Stock payable - 5,233 Accumulated deficit ( 99,289,095 ) ( 91,930,152 ) Total Stockholders' Equity 6,604,686 5,658,989 Total Liabilities and Stockholders' Equity $ 8,379,110 $ 6,754,146 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 Table of Contents ENDRA Life Sciences Inc. Condensed Consolidated S

View Full Filing

View this 10-Q/A filing on SEC EDGAR